Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end BGE-102 induced weight loss in preclinical obesity models, both as monotherapy and in combination with GLP-1 receptor ...

From trial phases to personalized care, here’s how healthcare providers can navigate cancer clinical trials and guide ...

That’s it for 2025’s Q1 clinical trials round-up. If you have a study that could fit the bill for our next column, please ...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced multiple clinical research results to be presented at the 2025 American Society of Clinical ...

The publication, titled “ FLT201, a novel liver-directed AAV gene therapy candidate for Gaucher disease Type 1 ,” highlights preclinical data showing that FLT201 outperformed both ERT and gene therapy ...

INOVIO (NASDAQ: INO) has announced its participation in a series of high-profile conferences in May, where it will showcase pivotal data on its lead DNA immunotherapy ...

Separately, Janux will host an R&D Day in mid-2025 highlighting product candidates identified from its preclinical pipeline to move into clinical trials. Janux’s first clinical candidate ...